Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.

NPJ Breast Cancer · 2026 · PMC13002980 · PMID 41667511

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendp = 0.059so close (0.05 < p ≤ 0.1)

Likelihood ratio testing confirmed that HER2DX metastatic score added significant prognostic information beyond ERBB2 for rwOS (χ2=10.944, p = 0.004) and showed a trend for rwPFS (χ2=5.673, p = 0.059).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.